Comparison between gemcitabine-based combination (G) and single-agent chemotherapy (S) for elderly patients (EP) with advanced non-small cell lung cancer (NSCLC): A literature-based meta-analysis

19586 Background: It was estimated that a quarter of all patients who have a diagnosis of NSCLC worldwide are more than 70 years old. This meta-analysis tries to shed light on the controversial results of phase III trials evaluating in NSCLC EP doublets against third generation S. Methods: We performed a literature search using MEDLINE and Cochrane Library. We selected only clinical trials responding to the question of our meta-analysis. Outcomes recorded were 1-year survival rate (1-y SR), overall response rate (ORR) and haematological toxicity (HT). Fixed-effects and random-effects models were used to calculate pooled odds ratios (OR). An OR greater than 1 indicates that doublet is more …

VEGF levels could affect outcomes in elderly breast cancer women

FULVESTRANT AND CAPECITABINE IN ELDERLY ADVANCED BREAST CANCER PATIENTS: THE PROPOSAL FOR AN EFFECTIVE AND SAFE COMBINED TREATMENT SCHEDULE.

SAFETY AND EFFICACY OF INHALED IL-2 THERAPY IN PRE-TREATED BREAST CANCER ELDERLY PATIENTS WITH PULMONARY METASTASES.